Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Immupharma confirms £8.4mln fundraise

Shares in ImmuPharma nudged higher as it confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor.
Immupharma confirms £8.4mln fundraise
Immupharma brought in £8.4mln from the placing and subscription

Shares in ImmuPharma (LON:IMM) nudged higher as it confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor.

It comes after it did receive VCT advance assurance and EIS advance assurances from HMRC which it required to raise a further £0.7mln.

The cash will be used to fund its share of the costs of developing Lupuzor, its potential blockbuster drug for the autoimmune disease Lupus, which is currently undergoing phase III clinical trials and also provide the firm with its working capital requirements through to 2018.

Shares added 2.06% on Tuesday Morning to stand at 24.75p.

Giles_55af4ddca6481.jpg
Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future IMM Company articles
View full IMM profile

ImmuPharma PLC Timeline

Related Articles

biotech_517925923_58abefa9e91cc.jpg
Tue
“Our strategy of investing in future capacity will ensure our ability to provide quality service for this high level of customer need as our partners’ programmes progress,” said chief executive John Burt.
AZN2.jpg
January 10 2017
We look at what looks to be a savvy investment by the UK biotech.
Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.